Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies

• Published in: Alimentary pharmacology & therapeutics 2005-06, Vol.21 (s2), p.32-36
• Main Authors: Seno, H., Nakase, H., Chiba, T.
• Format: Article
• Language: English
• Subjects: Anti-Anxiety Agents - therapeutic use; Anxiety Disorders - drug therapy; Benzamides - therapeutic use; Drug Therapy, Combination; Dyspepsia - drug therapy; Famotidine - therapeutic use; Female; Gastrointestinal Agents - therapeutic use; Humans; Isoindoles; Male; Middle Aged; Morpholines - therapeutic use; Piperazines - therapeutic use; Pyrimidines - therapeutic use; Serotonin Receptor Agonists - therapeutic use
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/j.1365-2036.2005.02471.x

Summary Background : The treatment of functional dyspepsia is controversial. Aim : The purpose of this paper is to clarify the initial effect of prokinetic, acid suppression and antianxiety treatment for functional dyspepsia patients. Patients and methods : Sixty‐four functional dyspepsia patients without Helicobacter pylori infection were randomly assigned to 15 mg/day of mosapride, 40 mg/day of famotidine, or 30 mg/day of tandospirone during an 8‐week treatment. Individual functional dyspepsia symptoms were evaluated with 4 cm visual analogue scale before and at 2, 4 and 8 weeks after treatment. Results : Among 64 enrolled patients, 62 completed the study. Within 2 weeks, visual analogue scale score in the mosapride‐treated group decreased from 2.29 ±0.14 to 1.57 ± 0.20; in the famotidine from 2.04 ± 0.16 to 1.09 ± 0.12 (mean ± S.E.). Therefore, there were significant improvements of functional dyspepsia symptoms in mosapride‐ and famotidine‐treated patients (P